About US
Contact us
-
Scotland’s NPSC and MRC sign MoU to accelerate drug discoveryThe National Phenotypic Screening Centre (NPSC) at the University of Dundee and the Medical Research Council (MRC) Centre for Regenerative Medicine (CRM) at the University of Edinburgh have signed a m2017/3/15
-
Vertex to acquire Concert Pharmaceuticals’ cystic fibrosis drug for $250mUS-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for u2017/3/15
-
Vernalis and Servier sign oncology drug discovery collaborationUK-based Vernalis and French pharmaceutical company Servier have entered a new oncology drug discovery collaboration. Under the latest two-year agreement, Vernalis' fragment-based and structure-based2017/3/14
-
Sanofi Pasteur and MedImmune to develop and commercialise MEDI8897France-based Sanofi Pasteur has signed an agreement with AstraZeneca’s global biologics research and development arm MedImmune to develop and commercialise a monoclonal antibody known as MEDI8897. ME2017/3/14
-
FDA approves Serenity’s Noctiva nasal spray for frequent night-time urinationThe US Food and Drug Administration (FDA) has approved Noctiva (desmopressin acetate) nasal spray treatment for adults who wake up at least two times every night due to overproduction of urine, a cond2017/3/13
-
NICE approves Intercept’s Ocaliva for use by UK's NHSThe National Institute for Health and Care Excellence (NICE) in the UK has approved Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for routine use by the National Health Service (NHS) in Englan2017/3/13
-
NICE recommends Merck’s Erbitux to treat patients with metastatic colorectal cancerThe UK National Institute for Health and Care Excellence (NICE) has issued a positive final appraisal determination (FAD) for Merck’s Erbitux (cetuximab) to treat patients with RAS wild-type metastati2017/3/10
-
J&J joins Pfizer, Celgene, Biogen and more in DOJ's patient-assistance dragnetPfizer isn’t the only Big Pharma targeted by the Justice Department for its contributions to patient-assistance charities. Johnson & Johnson has its own subpoena in hand, the companydisclosedin a2017/3/9
-
Prosecutors rope Pfizer into fast-growing copay assistance probeAdd Pfizer to thelist of the companies facing a governmental investigation about its ties to copay assistance programs. After first focusing on biotech and specialty pharma, the feds have made their2017/3/9
-
Biosimilars look like a good bet now. But will they later? Allergan CEO says maybe notCompanies are flocking to the biosimilars scene, eager to capture a piece of the market for the world’s best-selling biologic drug brands. But one CEO won’t be surprised if those biosim developers one2017/3/8